Clinical trial
Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in…
NCT00170209 · McGill University, Other · Completed
Key facts
| NCT number | NCT00170209 |
|---|---|
| Title | Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9) |
| Official title | A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial |
| Lead sponsor | McGill University, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Latent Tuberculosis Infection |
| Intervention type | Drug |
| Interventions | Isoniazid, Rifampin |
| Enrollment | 844 |
| Start date | Aug 1, 2011 |
| Primary completion | Nov 1, 2014 |
| Completion | May 1, 2015 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 19, 2017 |
| Countries | Australia, Benin, Brazil, Canada, Ghana, Guinea, Indonesia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: